TY - JOUR TI - ROS1 Asp2213Asn polymorphism is not associated with coronary artery disease in a Greek case-control study AU - Theodoraki, E.V. AU - Nikopensius, T. AU - Suhorutšenko, J. AU - Papamikos, V. AU - Kolovou, G.D. AU - Peppes, V. AU - Panagiotakos, D. AU - Limberi, S. AU - Zakopoulos, N. AU - Metspalu, A. AU - Dedoussis, G.V. JO - Clinical Chemistry and Laboratory Medicine (CCLM) PY - 2009 VL - 47 TODO - 12 SP - 1471-1473 PB - SN - null TODO - 10.1515/CCLM.2009.155 TODO - adult; article; case control study; controlled study; coronary artery disease; DNA polymorphism; female; genotype; Greece; human; major clinical study; male; morbidity; mutator gene; polymerase chain reaction; priority journal; risk assessment; ros1 gene; rs529038 gene, Aged; Asparagine; Aspartic Acid; Case-Control Studies; Female; Greece; Humans; Male; Middle Aged; Myocardial Infarction; Polymorphism, Genetic; Protein-Tyrosine Kinases; Proto-Oncogene Proteins TODO - Background: Rs619203 (Cys2229Ser) and rs529038 (Asp2213Asn) polymorphisms in the ROS1 gene have been studied in relation to myocardial infarction (MI) yielding inconsistent results. We investigated the role of ROS1 rs529038 polymorphism in coronary artery disease (CAD) in Greeks using a case-control study. Methods: Genotyping for rs529038 polymorphism was performed using a multiplex PCR technique in patients with CAD (n=294) and controls (n=311). Logistic regression analysis was used to calculate crude and adjusted odds ratios (ORs). Results: Logistic regression analysis did not show any statistically significant effect of ROS1 polymorphism in the occurrence of CAD (AG vs. AA, OR: 1.08, p=0.635; GG vs. AA, OR: 0.62, p=0.220). Adjustment for confounding factors gave similar results, irrespective of the type of disease (i.e., stable coronary artery disease vs. acute coronary syndrome). Conclusions: Our findings do not support the hypothesis that ROS1 rs529038 polymorphism is an important contributing factor in the etiology of CAD in the Greek population. © 2009 by Walter de Gruyter Berlin New York. ER -